Details

Autor(en) / Beteiligte

• Peters, Charles
• Charnas, Lawrence R.
• Tan, Ye
• Ziegler, Richard S.
• Shapiro, Elsa G.
• DeFor, Todd
• Grewal, Satkiran S.
• Orchard, Paul J.
• Abel, Susan L.
• Goldman, Anne I.
• Ramsay, Norma K.C.
• Dusenbery, Kathryn E.
• Loes, Daniel J.
• Lockman, Lawrence A.
• Kato, Shunichi
• Aubourg, Patrick R.
• Moser, Hugo W.
• Krivit, William

Titel

Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999

Ist Teil von

• Blood, 2004-08, Vol.104 (3), p.881-888

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Cerebral X-linked adrenoleukodystrophy (X-ALD) is a disorder of very-long-chain fatty acid metabolism, adrenal insufficiency, and cerebral demyelination. Death occurs within 2 to 5 years of clinical onset without hematopoietic cell transplantation (HCT). One hundred twenty-six boys with X-ALD received HCT from 1982 to 1999. Survival, engraftment, and acute graft-versus-host disease were studied. Degree of disability associated with neurologic and neuropsychological function and cerebral demyelination were evaluated before and after HCT. Complete data were available and analyzed for 94 boys with cerebral X-ALD. The estimated 5- and 8-year survival was 56%. The leading cause of death was disease progression. Donor-derived engraftment occurred in 86% of patients. Demyelination involved parietal-occipital lobes in 90%, leading to visual and auditory processing deficits in many boys. Overall 5-year survival of 92% in patients with 0 or 1 neurologic deficits and magnetic resonance imaging (MRI) severity score less than 9 before HCT was superior to survival for all others (45%; P < .01). Baseline neurologic and neuropsychological function, degree of disability, and neuroradiologic status predicted outcomes following HCT. In this first comprehensive report of the international HCT experience for X-ALD, we conclude that boys with early-stage disease benefit from HCT, whereas boys with advanced disease may be candidates for experimental therapies.